Loading data for GANX — first visit, this takes a few seconds.

알림

Gain Therapeutics Inc. (GANX)

NasdaqGM: GANX · 실시간 가격 · USD

2.17

+0.05 (2.36%)

종가 기준: Aug 13, 2026, 8:00 PM

2.12

-2.08%

프리마켓: 8:32 AM

2.36% (1D)

데이터 없음

매수호가	1.28
시가총액	92.35M
매출 (ttm)	n/a
순이익 (ttm)	-21.24M
베타	0.20
EPS (ttm)	-0.59
P/E (ttm)	n/a
선행 P/E	-3.8
P/B (ttm)	6.56
P/S (ttm)	n/a
Earnings Date	n/a

매도호가	2.27
거래량	1,327,502
평균 거래량 (20일)	896,577
시가	2.15
전일 종가	2.12
일중 범위	2.13 - 2.37
52주 범위	1.51 - 4.34
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

GANX 소개

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Mar 19, 2021

직원 수 20

상장 거래소 NasdaqGM

티커 GANX

웹사이트 https://gaintherapeutics.com

전체 기업 정보

재무 실적

2025년 Gain Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -20.16M로, -1.23% 감소했습니다.

재무제표

어닝 서프라이즈

Gain Therapeutics가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.11 예상치 상회 0.04, 및 42.11% 전년 대비 성장.

뉴스

1개월 전 · Stocktwits

Why Is GANX Stock Rallying 22% After Hours?

The U.S. Food and Drug Administration (FDA) cleared Gain Therapeutics to begin a mid-stage clinical trial of its experimental drug GT-02287 in people with Parkinson’s disease.

2개월 전 · Simply Wall St.

Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate

Gain Therapeutics’ Parkinson’s candidate GT-02287 showed durable clinical stability and biomarker improvements in extended Phase 1b data.

2개월 전 · Simply Wall St.

3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced

Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.

3개월 전 · InvestorsHub

Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss

Gain Therapeutics, Inc. (NASDAQ:GANX) shares rose 3.

3개월 전 · Simply Wall St.

3 US Biotechs Developing Parkinson’s Therapies

Global markets may be dealing with inflation, shifting rate expectations, and energy volatility, but companies tackling long-term health challenges like Parkinson’s disease are still pushing ahead.

2 페이지 중 1

Gain Therapeutics Inc. (GANX)